Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.36 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.36 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.36 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437554 | 0.91 | CYP2A6 (0.40) | ALDH1A1MAPK1USP2CYP26A1RXRA | |
| SCHEMBL1256099 | 0.87 | CHEK2 (0.39) | ALDH1A1MAPK1CHEK2OPRM1OPRK1 | |
| SCHEMBL21679404 | 0.86 | MAOA (0.38) | ALDH1A1TDP1MAPK1USP2CYP26A1 | |
| SCHEMBL27825774 | 0.84 | CHEK2 (0.38) | ALDH1A1MAPK1CHEK2OPRM1OPRK1 | |
| SCHEMBL28147803 | 0.82 | CHRNA1 (0.40) | ALDH1A1TDP1MAPK1CHEK2CYP26A1 | |
| SCHEMBL30959783 | 0.82 | CHRNA1 (0.40) | ALDH1A1TDP1MAPK1CHEK2CYP26A1 | |
| SCHEMBL3562339 | 0.82 | CNR1 (0.39) | ALDH1A1KDM1AMAPK1CHEK2CNR1 | |
| SCHEMBL17746142 | 0.81 | TAAR1 (0.39) | ALDH1A1TDP1KDM1ARCOR1MAPK1 | |
| SCHEMBL14081492 | 0.79 | OPRM1 (0.42) | CHEK2ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL11046196 | 0.79 | TSHR (0.46) | ALDH1A1MAPK1CHEK2CYP26A1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229288-B1 | POLYMER, AND MIXTURE, FORMULATION AND ORGANIC ELECTRONIC DEVICE CONTAINING THE SAME, AND MONOMER THEREOF | GUANGZHOU CHINARAY OPTOELECTRONIC MAT LTD (CN) | 2019-05-01 | — | — | EP | disclosed |
| EP-3229288-A1 | POLYMER, MIXTURE AND COMPOUND CONTAINING SAME, AND ORGANIC ELECTRONIC DEVICE AND MONOMER THEREOF | Guangzhou Chinaray Optoelectronic Materials Ltd. (CN) | 2017-10-11 | — | — | EP | disclosed |
| US-7687639-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-30 | — | — | US | disclosed |
| EP-1613313-B1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-4,5]-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-06 | — | — | EP | disclosed |
| US-20060252793-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | BW CONVERTING AB (SE) | 2006-11-09 | — | — | US | disclosed |
| US-7132440-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-07 | — | — | US | disclosed |
| EP-1613313-A1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-4,5!-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004093873-A1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-`4,5!-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214857-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-10-28 | — | — | US | disclosed |
| EP-0401798-B1 | Substituted aminoalkylbenzene derivatives | HOFFMANN LA ROCHE (CH) | 1995-01-11 | — | — | EP | disclosed |
| US-5137920-A | METHOD OF TREATING FUNGAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 1992-08-11 | — | — | US | disclosed |
| US-4051261-A | HYPOLIPIDEMIC, ANTIDIABETIC | SANDOZ, INC. (US) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252793-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDKN1A, DDB1, TMBIM6 | ALDH1A1 1427/4885TDP1 471/4885KDM1A 2167/4885 |
| US-20040214857-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDK4, CDS2, DDB1 | ALDH1A1 1463/4885TDP1 352/4885KDM1A 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.